MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio

MaxCyte, Inc. (NASDAQ:MXCT) is one of the Best 52-Week Low Penny Stocks to Buy NowOn August 4, MaxCyte, Inc. (NASDAQ:MXCT) announced signing a strategic platform license with Adicet Bio, Inc. Adicet focuses on developing allogeneic gamma delta T cell therapies for cancer and autoimmune diseases.

As part of this agreement, Adicet gets non-exclusive rights to use MaxCyte, Inc.’s (NASDAQ:MXCT) Flow Electroporation technology and ExPERT platform for research, clinical, and commercial purposes. The company has developed a unique process to activate and grow specific gamma delta T cells, enabling large-scale production of off-the-shelf cell therapies ready for clinical use. The approach combines non-viral gene editing with an efficient expansion system to create powerful therapies aimed at treating various cancers and autoimmune conditions. MaxCyte, Inc.’s (NASDAQ:MXCT) ExPERT technology offers advanced electroporation tools that ensure high gene transfer efficiency, cell viability, and scalability.

MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio

A close up shot of a researcher testing a drug for therapeutic applications.

MaxCyte, Inc. (NASDAQ:MXCT) develops advanced cell-engineering technologies to help biotech and pharmaceutical companies create next-generation cell therapies.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.